Estrogen and colon cancer:current issues

References

• Coleman MP, Babb P, Damiecki P, et al. Cancer Survival Trends in England and Wales, 1971–1995: Deprivation and NHS Region. London: The Stationery Office Publications Centre, 1999
   Google Scholar
• Bond JH. Colorectal cancer update. Prevention, screening, treatment, and surveillance for high-risk groups. Med Clin North Am 2000;84: 1163–82
   PubMed Web of Science ®Google Scholar
• Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993;15:499–545
   PubMed Web of Science ®Google Scholar
• Potter JD, Bostick RM, Gremdits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prey 1996;5: 779–84
   PubMed Web of Science ®Google Scholar
• Fraumeni JF Jr, Lloyd JW, Smith EM, Wagoner JK. Cancer mortality among nuns: role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst 1969;42:455–68
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Potter JD. Reproduction, endo-genous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980;65:1201–7
   PubMed Web of Science ®Google Scholar
• Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979;133:525–36
   PubMed Web of Science ®Google Scholar
• Furner SE, Davis FG, Nelson RL, Haenszel W. A case-control study of large bowel cancer andhormone exposure in women. Cancer Res 1989; 49:4936–40
   PubMed Web of Science ®Google Scholar
• Gerhardsson de Verdier M, London S. Reproduc-tive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control 1992;3:355–60
   PubMed Web of Science ®Google Scholar
• Jacobs EJ, White E, Weiss NS. Exogenous hor-mones, reproductive history, and colon cancer (Seattle, Washington, USA). Cancer Causes Control 1994;5:359–66
   Google Scholar
• Marcus PM, Newcomb PA, Young T, Storer BE. The association of reproductive and menstrual characteristics and colon and rectal cancer risk in Wisconsin women. Ann Epidemiol 1995;5: 303–9
   PubMedGoogle Scholar
• Newcomb PA,Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women [published erratum appears in Am J Epidemiol 1996;143:527]. Am J Epidemiol 1995;142:788–95
   PubMed Web of Science ®Google Scholar
• Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multi-center, case-control study in the United States. Cancer Causes Control 1997;8:146–58
   Google Scholar
• Fernandez E, LaVecchia C, Braga C, et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prey 1998;7: 329–33
   PubMed Web of Science ®Google Scholar
• Weiss NS, Dating JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst 1981;67:57–60
   PubMedGoogle Scholar
• Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 1983;71:703–9
   PubMed Web of Science ®Google Scholar
• Davis FG, Furner SE, Persky V, Koch, M. The influence of parity and exogenous female hor-mones on the risk of colorectal cancer. Int J Cancer 1989;43:587–90
   Google Scholar
• Peters RK, Pike MC, Chang WW, Mack TM. Reproductive factors and colon cancers. Br J Cancer 1990;61:741–8
   PubMed Web of Science ®Google Scholar
• Wu-Williams AH, Lee M, Whittemore AS, et al. Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 1991;51: 2307–11
   PubMed Web of Science ®Google Scholar
• Burch JC, Byrd BF, Vaughn WK. The effects of long-term estrogen administration to women following hysterectomy. Front Horm Res 1975; 3:208–14
   Google Scholar
• Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohortof postmenopausal women. J Natl Cancer Inst 1995;87:517–23
   PubMed Web of Science ®Google Scholar
• Folsom AR, Mink PJ, Sellers TA, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of post-menopausal women. Am J Pub Health 1995;85: 1128–32
   PubMed Web of Science ®Google Scholar
• Grodstein F, Newcomb PA, Stampfer MJ. Post-menopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574–82
   Google Scholar
• Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen—progestin replacement therapy — long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327–32
   PubMed Web of Science ®Google Scholar
• Troisi R, Schairer C, Chow WH, et al. A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes Control 1997;8:130–8
   PubMed Web of Science ®Google Scholar
• Wu AH, Paganini-Hill A, Ross RK, Henderson BE. Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer 1987;55:687–94
   PubMed Web of Science ®Google Scholar
• Risch HA, Howe GR. Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Bio-markers Prey 1995;4:21–8
   PubMed Web of Science ®Google Scholar
• MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust 1995;162:491–3
   Google Scholar
• Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. 0 bstet Gynecol 1999;93:880–8
   PubMed Web of Science ®Google Scholar
• Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 1999;8:1155–66
   PubMedGoogle Scholar
• Hebert-Croteau NA. Meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prey 1998;7: 653–9
   PubMed Web of Science ®Google Scholar
• Peipins LA, Burnett C, Alterman T, Lalich N. Mortality patterns among female nurses: a 27-state study, 1984 through 1990. Am J Public Health 1997;87:1539–43
   PubMed Web of Science ®Google Scholar
• Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128:705–12
   PubMed Web of Science ®Google Scholar
• Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995;6:227–31
   Google Scholar
• Jednak MA, Nostrant TT. Screening for colo-rectal cancer. Prim Care 1998;25:293–308
   PubMedGoogle Scholar
• Schoen RE, Weissfeld JL, KuIler LH. Are women with breast, endometrial, or ovarian cancer at increased risk for colorectal cancer? Am J Gastroenterol 1994;89:835–42
   Google Scholar
• Eisen GM, Sandler RS. Are women with breast cancer more likely to develop colorectal cancer? Critical review and meta-analysis. J Clin Gastro-enterol 1994;19:57–63
   PubMed Web of Science ®Google Scholar
• Burnand B, Bochud M, Froehlich F, et al. Appropriateness of colonoscopy: screening for colorectal cancer in asymptomatic individuals. Endoscopy 1999;31:673–83
   PubMed Web of Science ®Google Scholar
• Schatzkin A, Baranovsky A, Kessler LG. Diet and cancer. Evidence from associations of multiple primary cancers in the SEER program. Cancer 1988;62:1451–7
   Google Scholar
• Neugut AI, Murray TI, Lee WC, Robinson E. The association of breast cancer and colorectal cancer in men. An analysis of surveillance, epidemio-logy, and end results program data. Cancer 1991;68:2069–73
   Google Scholar
• Newschaffer CJ, Topham A, Herzberg T, Weiner S, Weinberg DS. Risk of colorectal cancer after breast cancer. Lancet 2001;357:837–40
   Google Scholar
• Lin KM, Ternent CA, Adams DR, et al. Colorectal cancer in hereditary breast cancer kindreds. Dis Colon Rectum 1999;42:1041–5
   PubMed Web of Science ®Google Scholar
• The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310–16
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343: 692–5
   Google Scholar
• Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645–51
   PubMed Web of Science ®Google Scholar
• Curtis RE, Boice JD Jr, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88:832–4
   PubMed Web of Science ®Google Scholar
• Oshima CT, Wonraht DR, Catarino RM, Mattos, D, Forones NM. Estrogen and progester-one receptors in gastric and colorectal cancer. Hepatogastroenterology 1999;46:3155–8
   PubMed Web of Science ®Google Scholar
• Salih MA, Sims SH, Kalu DN. Putative intestinal estrogen receptor: evidence for regional differ-ences. Mol Cell Endocrinol 1996;121:47–55
   Google Scholar
• Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000;24:145–55
   PubMed Web of Science ®Google Scholar
• Slattery ML, Samowitz WS, Holden JA. Estrogen and progesterone receptors in colon tumors. Am J Clin Patbol 2000;113:364–8
   Google Scholar
• Foley EF, Jazaeri AA, Shupnik MA, Jazaeri 0, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000; 60:245–8
   Google Scholar
• FioreIli G, Picariello L, Martineti V, ToneIli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biocbem Biophys Res Commun 1999;261:521–7
   PubMedGoogle Scholar
• Lointier P, Wildrick DM, Boman BM. Growth effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa. Anticancer Res 1992;12:1523–5
   Google Scholar
• Xu X, Thomas ML. Estrogen receptor-mediated direct stimulation of colon cancer cell growth in vitro. Mol Cell Endocrinol 1994;105:197–201
   PubMed Web of Science ®Google Scholar
• Arai N, Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor beta mRNA in colon cancer cells: growth effects of estrogen and genistein. Biocbem Biophys Res Commun 2000;270: 425–31
   PubMed Web of Science ®Google Scholar
• English MA, Kane KF, Cruickshank N, et al. Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab 1999; 84:2080–5
   PubMed Web of Science ®Google Scholar
• English MA, Hughes SV, Kane KF, et al. Oestrogen inactivation in the colon: analysis of the expression and regulation of 17beta-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer. Br J Cancer 2000;83:550–8
   PubMed Web of Science ®Google Scholar
• Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biocbem Mol Biol 1999;71:223–30
   PubMed Web of Science ®Google Scholar
• Issa JP. The epigenetics of colorectal cancer. Ann NY Acad Sci 2000;910:140-53, discussion 153–5
   Google Scholar
• Cedar H. DNA methylation and gene activity. Cell 1988;53:3–4
   PubMed Web of Science ®Google Scholar
• Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a funda-mental aspect of neoplasia. Adv Cancer Res 1998;72:141–96
   Google Scholar
• Singer-Sam J, Riggs AD. X chromosome inactivation and DNA methylation. EXS 1993; 64:358–84
   Google Scholar
• Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536–40
   PubMed Web of Science ®Google Scholar
• Watts CK, Parker MG, King RJ. Stable trans-fection of the oestrogen receptor gene into a human osteosarcoma cell line. J Steroid Biocbem 1989;34:483–90
   Google Scholar
• Maminta ML, Molteni A, Rosen ST. Stable expression of the human estrogen receptor in HeLa cells by infection: effect of estrogen on cellproliferation and c-myc expression. Mol Cell Endocrinol 1991;78:61–9
   Google Scholar
• Ma ZQ, Spreafico E, Pollio G, et al. Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci USA 1993;90:3740–4
   PubMed Web of Science ®Google Scholar
• Garcia M, Derocq D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 1992;89:11538–42
   PubMed Web of Science ®Google Scholar
• Zajchowski DA, Sager R, Webster L. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombi-nant estrogen receptor. Cancer Res 1993;53: 5004–11
   Google Scholar
• Jiang SY, Jordan VC. Growth regulation of estro-gen receptor-negative breast cancer cells trans-fected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992;84:580–91
   PubMed Web of Science ®Google Scholar
• Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methy-lation and increased mRNA and protein expres-sion of the colonic vitamin D receptor. Oncol Res 1999;11:255–64
   Google Scholar
• Ottaviano YL, Issa JP, Parl FF, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552–5
   PubMed Web of Science ®Google Scholar
• Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997;11: S7–11
   Google Scholar
• Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen expo-sure. Cancer Res 1996;56:3655–8
   Google Scholar
• Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43: 985–91
   PubMed Web of Science ®Google Scholar
• Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351: 453–6
   Google Scholar
• Horvath G, Leser G, Delle U. Protein expression of p53 and Rb suppressor genes during the first passages of human endometrial adeno-carcinomas heterotransplanted into nude mice. In Vivo 1995;9: 41–8
   Google Scholar
• Horvath G, Leser G, Karlsson L, Delle U. Estradiol regulates tumor growth by influencing p53 and bc1-2 expression in human endometrial adenocarcinomas grown in nude mice. In Vivo 1996;10:411–16
   PubMed Web of Science ®Google Scholar
• Yue W, Brodie AM. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostene-dione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture. J Steroid Bio-chem Mol Biol 1997;63:317–28
   PubMed Web of Science ®Google Scholar
• Reddy BS, Rao CV. Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging 2000;16: 329–34
   PubMed Web of Science ®Google Scholar
• Chung FL, Conaway CC, Rao CV, Reddy BS. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phen-ethyl isothiocyanate. Carcinogenesis 2000;21: 2287–91
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Crowell JA, Steele VE, et al. Progress in cancer chemoprevention. Ann NY Acad Sci 1999;889:1–13
   PubMed Web of Science ®Google Scholar
• Decensi A, Costa A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur J Cancer 2000;36: 694–709
   PubMed Web of Science ®Google Scholar